FDA cracking down telehealth companies On March 2, the FDA announced it sent 30 letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites
These real stories highlight personal experiences, lifestyle changes, and program support shared by individuals who chose a medically guided approach to weight management
Special Considerations and Interactions FDA-Approved Oral Semaglutide May Not Work Well If You Have: Gastrointestinal disorders affecting absorption Liver conditions Difficulty maintaining strict morning medication routines Compounded ODT Formulations Considerations: Not FDA-approved
Its also relatively uncommon, occurring in less than 5% of people, based on available clinical data, and typically only affects hair on the scalp
As a result, SWMPs must evolve strategically to remain relevant and clarify their role in the changing landscape of obesity treatment
Such muscle loss can have significant implications for physical strength and functionality
